会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 32. 发明申请
    • LIGANDS FOR PHOSPHATASE BINDING ASSAY
    • 用于磷酸酶结合测定的配体
    • WO1998020024A1
    • 1998-05-14
    • PCT/CA1997000824
    • 1997-11-03
    • MERCK FROSST CANADA INC.DESMARAIS, SylvieFRIESEN, RichardZAMBONI, Robert
    • MERCK FROSST CANADA INC.
    • C07K05/08
    • C07K5/0827
    • Disclosed are new ligands for use in a binding assay for proteases and phosphatases, which contain cysteine in their binding sites or as a necessary structural component for enzymatic binding. The sulfhydryl group of cysteine is the nucleophilic group in the enzyme's mechanistic proteolytic and hydrolytic properties. The assay can be used to determine the ability of new, unknown ligands and mixtures of compounds to competitively bind with the enzyme versus a known binding agent for the enzyme, e.g., a known enzyme inhibitor. By the use of a mutant form of the natural or native wild-type enzyme, in which serine, or another amino acid, e.g., alanine, replaces cysteine, the problem of interference from extraneous oxidizing and alkylating agents in the assay procedure is overcome. The interference arises because of oxidation or alkylation of the sulfhydryl, -SH (or -S ), in the cysteine, which then adversely affects the binding ability of the enzyme. Specifically disclosed is an assay for tyrosine phosphatases and cysteine proteases, including capsases and cathepsins, e.g., Cathepsin K(O2), utilizing scintillation proximity assay (SPA) technology. The assay has important applications in the discovery of compounds for the treatment and study of, for example, diabetes, immunosuppression, cancer, Alzheimer's disease and osteoporosis. The novel feature of the use of a mutant enzyme can be extended to its use in a wide variety of conventional colorimetric, photometric, spectrophotometric, radioimmunoassay and ligand-binding competitive assays.
    • 公开了用于蛋白酶和磷酸酶的结合测定的新配体,其在其结合位点含有半胱氨酸或作为酶结合的必需结构组分。 半胱氨酸的巯基是酶的机理蛋白水解和水解性质中的亲核基团。 该测定法可用于测定新的未知配体和化合物的混合物与酶竞争性结合的能力,与酶的已知结合剂,例如已知的酶抑制剂。 通过使用天然或天然野生型酶的突变形式,其中丝氨酸或另一种氨基酸例如丙氨酸取代半胱氨酸,克服了测定程序中来自外来氧化和烷化剂的干扰问题。 干扰是由于半胱氨酸中巯基-SH(或-S - )的氧化或烷基化而产生的,其然后不利地影响酶的结合能力。 具体公开的是利用闪烁亲近测定(SPA)技术测定酪氨酸磷酸酶和半胱氨酸蛋白酶,包括热囊酶和组织蛋白酶,例如组织蛋白酶K(O 2)。 该测定在发现用于治疗和研究例如糖尿病,免疫抑制,癌症,阿尔茨海默氏病和骨质疏松症的化合物中具有重要应用。 使用突变酶的新颖特征可以扩展到其用于各种常规比色,光度,分光光度,放射免疫测定和配体结合竞争性测定中。
    • 37. 发明申请
    • INHIBITORS OF PICORNAVIRUS PROTEASES
    • PICORNAVIRUS蛋白抑制剂
    • WO1992022570A1
    • 1992-12-23
    • PCT/US1992005167
    • 1992-06-12
    • CHIRON CORPORATION
    • CHIRON CORPORATIONMALCOLM, BruceYANG, Chi, Ching
    • C07K05/08
    • C07K7/06C07K5/0808C07K14/005C12N2770/32022
    • Compounds of formula (I) inhibit the proteolytic activity of picornaviral proteases, and are thus effective antiviral agents. In formula (I) R1 is -OR3 or -NR3R4, where R3 is lower alkyl, hydroxy, lower alkoxy, or aryl-lower alkyl, and R4 is H or lower alkyl; R2 is H or lower acyl; n is an integer from 2 to 40 inclusive; X is an anchor group selected from the group consisting of -CHO, -C=N, -COCH2F, -COCH2Cl, -COCH2N2, -CH=N-NHC(=S)NH2 or -COCOR5 where R5 is lower alkyl, lower alkoxy, lower aryl, aryl-lower alkyl or aryl-lower alkoxy; and aa indicates an amino acid; wherein (aa)n is an amino acid sequence recognized specifically by said selected protease.
    • 式(I)化合物抑制微小RNA病毒蛋白酶的蛋白水解活性,因此是有效的抗病毒剂。 在式(I)中,R 1是-OR 3或-NR 3 R 4,其中R 3是低级烷基,羟基,低级烷氧基或芳基 - 低级烷基,R 4是H或低级烷基; R2是H或低级酰基; n为2〜40的整数, X是选自-CHO,-C = N,-COCH2F,-COCH2Cl,-COCH2N2,-CH = N-NHC(= S)NH2或-COCOR5的锚定基团,其中R5是低级烷基,低级烷氧基 ,低级芳基,芳基 - 低级烷基或芳基 - 低级烷氧基; 和aa表示氨基酸; 其中(aa)n是所述选择的蛋白酶特异性识别的氨基酸序列。
    • 38. 发明申请
    • KININOGENASE INHIBITORS
    • 基因抑制剂
    • WO1992004371A1
    • 1992-03-19
    • PCT/GB1991001479
    • 1991-09-02
    • FERRING PEPTIDE RESEARCH PARTNERSHIP KBSZELKE, MichaelEVANS, David, MichaelJONES, David, Michael
    • FERRING PEPTIDE RESEARCH PARTNERSHIP KB
    • C07K05/08
    • C07K5/02C07K5/0227
    • Kininogenase inhibitors, optimally not exceeding the size of a hexapeptide, represented by (II), wherein A and B = amino acyl (including amino acyl analogue) the same or different forming a dipeptide group the amino acid of A carrying a terminal group and being any amino or imino-acid residue (but preferably of D-configuration) and of B being a lipophilic amino-acid residue of D- or L-configuration but not proline or a proline analogue, or a conformational analogue of said dipeptide group wherein the peptide link is replaced by -CH2-NH- ('reduced'), -CH(OH)-CH2- ('hydroxy'), -CO-CH2 ('keto'), -CH2-CH2- ('hydrocarbon') or other conformational mimic of the peptide bond and in (III) the side chain R is that of a basic amino acid or amino acid analogue (preferably of L-configuration), and R is H or lower alkyl(C1-C4) or C or the peptide link comprising -N(R)- is replaced leading to a conformational mimic as above; Y = a binding enhancing or carbonyl activating group preferably selected from H (when A or B must be cyclohexylalanine, preferably D if at A or L if at B) or alkyl (C1-C20) or fluoroalkyl (C2-C12); substituted oxymethylene; thiomethylene; sulphoxymethylene; sulphonylmethylene; aminomethylene; hydrazino-methylene; -CH2-Het (where Het = a substituted or unsubstituted heterocycle); substituted amino (but when the resulting compound is a secondary alkylamide B must not be phenylalanine); an amino-acid group or its ester or amide; a carboxylic secondary amide or primary amide, when B must be cyclohexylalanine or adamantylalanine or other bulky lipophilic, non-aromatic amino-acid (not Ala Leu Ile Val Nva Met Nle Phe Tyr Trp Nal (1)); tertiary-carboxamide; carboxy-alkyl group or its ester or amide or amino acyl derivative.
    • 激肽原酶抑制剂最好不超过由(II)表示的六肽的大小,其中A和B =氨基酰基(包括氨基酰基类似物)相同或不同,形成携带末端基团的A的氨基酸的二肽基团 任何氨基或亚氨基酸残基(但优选D构型)和B是D-或L-构型的亲脂性氨基酸残基,但不是脯氨酸或脯氨酸类似物或所述二肽基团的构象类似物,其中 肽链连接被-CH 2 -NH-(“还原”),-CH(OH)-CH 2 - ('羟基'),-CO-CH 2('酮基),-CH 2 -CH 2 - (“烃基” 或其它构型模拟物,并且在(III)中,侧链R 1是碱性氨基酸或氨基酸类似物(优选L-构型)的那些,并且R是H或低级烷基(C1-C4 )或Cα或包含-N(R) - 的肽连接被取代,导致如上所述的构象模拟物; Y =优选选自H的结合增强或羰基活化基团(当A或B必须为环己基丙氨酸时,优选D,如果在A或L,如果在B)或烷基(C 1 -C 20)或氟代烷基(C 2 -C 12); 取代的甲醛; 硫代亚甲基; sulphoxymethylene; sulphonylmethylene; 氨基亚甲基; 肼基的亚甲基; -CH 2 -Het(其中Het =取代或未取代的杂环); 取代的氨基(但当所得化合物为仲烷基酰胺B时,不得为苯丙氨酸); 氨基酸基或其酯或酰胺; 当B必须为环己基丙氨酸或金刚烷基丙氨酸或其它大体积的亲脂性非芳族氨基酸(不是Ala Leu Ile Val Nva Met Nle Phe Tyr Trp Nal(1))时,羧基仲酰胺或伯酰胺; 叔酰胺; 羧基 - 烷基或其酯或酰胺或氨基酰基衍生物。